A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
High expression of ERBB2 has been reported in medulloblastoma and ependymoma; EGFR is amplified and over-expressed in brainstem glioma suggesting these proteins as potential therapeutic targets. We conducted a molecular biology (MB) and phase II study to estimate inhibition of tumor ERBB signaling and sustained responses by lapatinib in children with recurrent CNS malignancies. In the MB study, patients with recurrent medulloblastoma, ependymoma, and high-grade glioma (HGG) undergoing resection were stratified and randomized to pre-resection treatment with lapatinib 900 mg/m2 dose bid for 7–14 days or no treatment. Western blot analysis of ERBB expression and pathway activity in fresh tumor obtained at surgery estimated ERBB receptor signaling inhibition in vivo. Drug concentration was simultaneously assessed in tumor and plasma. In the phase II study, patients, stratified by histology, received lapatinib continuously, to assess sustained response. Eight patients, on the MB trial (four medulloblastomas, four ependymomas), received a median of two courses (range 1–6+). No intratumoral target inhibition by lapatinib was noted in any patient. Tumor-to-plasma ratios of lapatinib were 10–20 %. In the 34 patients (14 MB, 10 HGG, 10 ependymoma) in the phase II study, lapatinib was well-tolerated at 900 mg/m2 dose bid. The median number of courses in the phase II trial was two (range 1–12). Seven patients (three medulloblastoma, four ependymoma) remained on therapy for at least four courses range (4–26). Lapatinib was well-tolerated in children with recurrent or CNS malignancies, but did not inhibit target in tumor and had little single agent activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000446 · Cited by 351 · cited 1×
“[15] in their studies of adult glioblastoma (*900–5,000 ng/ml in the 2 studies); however, we observed much lower lapatinib levels in tumor (*10–20 % of simultaneous plasma sample).”
BackgroundGajjar, A., Hernan, R., Kocak, M., Fuller, C., Lee, Y., McKinnon, P. J., Wallace, D., Lau, C., Chintagumpala, M., Ashley, D. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.032 · Cited by 279
Self-citation
Cited by
Pediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 360
Self-citationClinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.038 · Cited by 141
Hingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0758 · Cited by 28
Francis, J. H., Canestraro, J., Haggag-Lindgren, D., Harding, J. J., Diamond, E. L., Drilon, A., Li, B. T., Iyer, G., Schram, A. M., & Abramson, D. H. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.06.001 · Cited by 15
Metadata
- Authors
- Fouladi, M., Stewart, C. F., Blaney, S. M., Onar-Thomas, A., Schaiquevich, P., Packer, R. J., Goldman, S., Geyer, J. R., Gajjar, A., Kun, L. E., Boyett, J. M., & Gilbertson, R. J.
- Venue
- Journal of Neuro-Oncology
- Published
- 2013-07-09
- Volume
- 114
- Issue
- 2
- Pages
- 173-179
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W1998310148
- Cited by
- 66
- References
- 2
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. https://app.cochat.ai/papers/10.1007/s11060-013-1166-7
- The paper
- Fouladi, M., Stewart, C. F., Blaney, S. M., Onar-Thomas, A., Schaiquevich, P., Packer, R. J., Goldman, S., Geyer, J. R., Gajjar, A., Kun, L. E., Boyett, J. M., & Gilbertson, R. J. (2013). A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-013-1166-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.